Clinical and economic burden of community-acquired pneumonia among adults in the Czech Republic, Hungary, Poland and Slovakia

PLoS One. 2013 Aug 6;8(8):e71375. doi: 10.1371/journal.pone.0071375. Print 2013.


We estimate and describe the incidence rates, mortality, and cost of CAP (community-acquired pneumonia), in both inpatient and outpatient settings, in the Czech Republic (CZ), Slovakia (SK), Poland (PL), and Hungary (HU). A retrospective analysis was conducted on administrative data from the health ministry and insurance reimbursement claims with a primary diagnosis of pneumonia in 2009 to determine hospitalization rates, costs, and mortality in adults ≥50 years of age. Patient chart reviews were conducted to estimate the number of outpatient cases. Among all adults ≥50 years, the incidence of hospitalized CAP per 100,000 person years was: 456.6 (CZ), 504.6 (SK), 363.9 (PL), and 845.3 (HU). The average fatality rate for all adults ≥50 is 19.1%, and for each country; 21.7% (CZ), 20.9% (SK), 18.6% (PL), 17.8% (HU). Incidence, fatality, and likelihood of hospitalization increased with advancing age. Total healthcare costs of CAP in EUR was 12,579,543 (CZ); 9,160,774 (SK); 22,409,085 (PL); and 18,298,449 (HU); with hospitalization representing over 90% of the direct costs of treatment. The burden of CAP increases with advancing age in four CEE countries, with hospitalizations driving the costs of CAP upwards in the elderly population. Mortality rates are generally higher than reported in Western EU countries.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Community-Acquired Infections / economics*
  • Community-Acquired Infections / epidemiology*
  • Cost of Illness
  • Czech Republic / epidemiology
  • Humans
  • Hungary / epidemiology
  • Incidence
  • Middle Aged
  • Mortality
  • Pneumonia / economics*
  • Pneumonia / epidemiology*
  • Poland / epidemiology
  • Slovakia / epidemiology

Grant support

This study was sponsored by Pfizer Inc. CR and PH are co-authors of the manuscript. The funders had no role in study design, data collection and analysis; they, however, revised and authorized the manuscript for publishing.